VITAMIN A DERIVATIVES USE IN THE TREATMENT OF SKIN CONDITIONS
Retinoids are used to treat various skin diseases. They add valuable impact of when used early in the treatment of dermatological conditions. Overall vitamin A derivatives are underused, with isotretinoin is the most used. This paper aims to develop prescribers’ knowledge about their benefits, to improve their usability and aids in alleviating patient concerns to improve therapeutic outcomes in dermatological conditions. In acne vulgaris, adapalene gel and tretinoin cream showed equal efficacy. In psoriasis the combination of acitretin and PUVA was superior to PUVA alone. Acitretin showed a reduction of 41% in the Nail Psoriasis Severity Index and similar efficacy to potent steroids and calcipotriol. In chronic hand eczema, alitretinoin showed 50% improvement in patient’s refractory to steroid treatment. In photoaging and aging, retinoids were shown to increase the synthesis and decrease the degradation rate of collagen and hyaluronate, reducing the impact of aging. In rosacea, topical and systemic isotretinoin showed complete remission in 24% of the patients compared to only 14 % with antibiotics (metronidazole and doxycycline). In lichen planus, isotretinoin demonstrated clinical and histopathological efficacy. In cutaneous T-cell lymphoma, bexarotene used alone or with PUVA or narrow band UVB, showed a response between 80.0% to 84.0%. Lastly in Kaposi sarcoma alitretinoin gel showed superiority to all other agents and better tolerance. This review highlights the benefit of timely use of vitamin A derivatives to encourage wider use.
2. Science Direct. Available from: https://www. sciencedirect.com/topics/neuroscience/retinoic-acid-receptor [Last accessed on 23 Jul 2020].
3. Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatol Treat 2017;28:684-96.
4. Archana J, Bhargavi V. Retinoids-an overview of clinical applications in dermatology. J Pharm Sci Res 2010;2:376-83.
5. Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry 2012;73:37-50.
6. Ludot M, Mouchabac S, Ferreri F. Inter-relationships between isotretinoin treatment and psychiatric disorders: depression, bipolar disorder, anxiety, psychosis and suicide risks. World J Psychiatry 2015;5:222.
7. Layton A, Dreno B, Gollnick H, Zouboulis C. A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Academy Dermatol Venereol 2006;20:773-6.
8. Layton A. The use of isotretinoin in acne. Dermato-Endocrinol 2009;1:162-9.
9. Increased interferon-[gamma], interleukin-12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood mononuclear cells from a patient with acne vulgaris (Report). J Dermatol Sci 2009;55:47.
10. Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, et al. Systemic Isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012;132:2198-205.
11. Thielitz A, Abdel Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne–an evidence?based overview. JDDG: J Deutschen Dermatol Gesellschaft 2008;6:1023-31.
12. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945-73. e33.
13. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind, randomized trial. Cutis 2002;69:12-9.
14. Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002;12:350-4.
15. Carretero G, Ribera M, Belinchon I, Carrascosa JM, Puig L, Ferrandiz C, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis group of the spanish academy of dermatology and venereology. Actas Dermosifiliogr 2013;104:598-616.
16. van de Kerkhof PCM. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006;19:252-63.
17. Sommerburg C, Kietzmann H, Eichelberg D, Goos M, Heese A, Holzle E, et al. Acitretin in combination with PUVA: a randomized, double?blind placebo?controlled study in severe psoriasis. J European Academy Dermatol Venereol 1993;2:308-17.
18. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009;145:269-71.
19. Grønhøj Larsen F, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993;100:623-7.
20. Rollman O, Vahlquist A. Retinoid concentrations in the skin, serum and adipose tissue of patients treated with etretinate. Br J Dermatol 1983;109:439-47.
21. Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol 2005;6:255-72.
22. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64.
23. Blair H, Scott L. Alitretinoin: a review in severe chronic hand eczema. Drugs 2016;76:1271-9.
24. Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9? cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double?blind, placebo?controlled, multicentre trial. Br J Dermatol 2008;158:808-17.
25. Zussman J, Ahdout J, Kim J. Vitamins and photoaging: Do scientific data support their use? J Am Acad Dermatol 2010;63:507-25.
26. Sorg O, Kuenzli S, Kaya G, Saurat J. Proposed mechanisms of action for retinoid derivatives in the treatment of skin aging. J Cosmetic Dermatol 2005;4:237-44.
27. Altinyazar HC, Koca R, Tekin NS, Esturk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005;44:252-5.
28. Gollnick H, Blume Peytavi U, Szabo EL, Meyer K, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea–doxycycline? and placebo?controlled, randomized clinical study. JDDG: J Deutschen Dermatol Gesellschaft 2010;8:505-14.
29. Petruzzi M, Lucchese A, Lajolo C, Campus G, Lauritano D, Serpico R. Topical retinoids in oral lichen planus treatment: an overview. Dermatology 2013;226:61-3.
30. Schadt CR. Topical and oral bexarotene. Dermatol Ther 2013;26:400-40.
31. Hamada T, Tokura Y, Sugaya M, Ohtsuka M, Tsuboi R, Nagatani T, et al. Long?term efficacy and safety of bexarotene for Japanese patients with cutaneous T?cell lymphoma: the results of a phase 2 study (B?1201. J Dermatol 2019;46:557-63.
32. Morita A, Tateishi C, Muramatsu S, Kubo R, Yonezawa E, Kato H, et al. Efficacy and safety of bexarotene combined with photo (chemo) therapy for cutaneous T-cell lymphoma. J Dermatol 2020;47:443-51.
33. Walmsley WS, Northfelt ED, Melosky EB, Conant EM, Friedman Kien E, Wagner EB. Treatment of AIDS-related cutaneous kaposi?s sarcoma with topical alitretinoin (9-cis-Retinoic Acid) gel. JAIDS J Acquired Immune Defic Syndromes 1999;22:235-46.
This work is licensed under a Creative Commons Attribution 4.0 International License.